Thrombopoietin Receptor (TPO)

Eltrombopag is an agonist of the Thrombopoietin (Tpo) receptor, used as treatment for thrombocytopenia.

Megakaryocytes/platelets inducing agent is an inducing agent for megakaryocytes and/or platelets from pluripotent stem cells, the inducing agent being useful in treating diseases involving thrombopenia.

Avatrombopag is a novel orally-active thrombopoietin (TPO) receptor agonist.

Lusutrombopag, also known as S-888711, is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.

TPO agonist 1 can increase production of platelets by stimulating the TPO receptor in people with chronic ITP.

Eltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis.

Thrombopoietin Human Recombinant, HEK

Thrombopoietin Human Recombinant

Thrombopoietin Mouse Recombinant

ThrombopoietinHuman Recombinant, His Tag

Totrombopag is an orally active thrombopoietin receptor (TpoR) agonist. It activates TpoR, triggering an intracellular signaling cascade involving JAK2 kinase and the transcription factor Stat5, which is crucial for the regulation of megakaryocyte growth and differentiation into platelets. This compound is valuable for research into platelet production and the biology of megakaryocytes.

Totrombopag choline is a potent thrombopoietin receptor (TpoR) agonist that effectively stimulates megakaryocyte growth and platelet production. By activating TpoR, it triggers a signaling cascade involving JAK2 kinase and Stat5, which plays a crucial role in megakaryocyte differentiation. This compound is valuable for research focused on platelet biology and the mechanisms regulating thrombopoiesis.